Sometimes good news just isn't good enough. Waters Corporation (WAT) delivered a solid fourth quarter that beat Wall Street's expectations, but the stock got hammered Monday after the company issued first-quarter guidance that fell well short of what analysts were hoping for.

The Numbers That Actually Looked Pretty Good

Waters posted quarterly sales of $932.36 million for Q4 2025, representing a 7% increase as reported and 6% growth in constant currency. That topped the consensus estimate of $928.09 million. Adjusted earnings came in at $4.53 per share, narrowly beating the $4.51 consensus.

The breakdown shows where the strength came from. Instrument system sales increased 3% both as reported and in constant currency. The real star was recurring revenues, which combine service and precision chemistries, jumping 10% as reported and 9% in constant currency. That's the kind of sticky revenue that companies love.

Geographically, the picture was mixed but generally positive. Asia saw sales climb 4% as reported and 11% in constant currency. The Americas posted 4% growth. Europe showed 13% growth as reported, though that narrowed to 4% in constant currency. Not everything was rosy though—sales into the academic and government market declined 2% as reported and 3% in constant currency.

Why the Market Isn't Impressed

The problem wasn't what Waters did last quarter. It's what the company expects to do next quarter. Management guided first-quarter 2026 adjusted earnings to $2.25-$2.35 per share, significantly below the consensus estimate of $2.52. That's the kind of miss that makes investors nervous, even if sales guidance of $1.198-$1.211 billion seems reasonable.

For the full fiscal year 2026, Waters is calling for adjusted earnings of $14.30-$14.50 per share versus the consensus of $14.29, with sales projected between $6.41 billion and $6.46 billion. The full-year outlook is essentially in line with expectations, but that weak first quarter clearly rattled investors.

Management Stays Optimistic

"We expect this momentum to continue into 2026, driven by strong execution of the multi-year instrument replacement cycle, continued contribution from pioneering innovation, and our Waters-specific idiosyncratic growth drivers," said Udit Batra, President and CEO of Waters Corporation.

Batra added that the company expects to make "decisive progress" toward realizing cost synergies in the coming months. "Our starting 2026 guidance calls for an attractive 5.3% combined company sales growth at mid-point, with opportunity for outperformance as the year progresses," he noted.

What Analysts Are Saying

Not everyone is bearish on the story. William Blair maintained a positive stance in a Monday investor note, writing that "Waters' leadership position in the QA/QC market benefits from multiple sector-level and idiosyncratic tailwinds, and the company is in the early to middle innings of a long-overdue replacement cycle."

Analyst Matt Larew pointed to the acquisition of BD Bio/Dx as a meaningful TAM expander with conservative cost synergies and achievable revenue synergies that should drive upside. "'New Waters' should continue to have above-group growth, margins, and ROIC—thus, we expect the company to maintain a premium multiple," Larew added.

The market wasn't buying that optimism on Monday. Shares of Waters dropped 9.61% to $344.66, proving once again that near-term guidance can matter more than recent results.